The company stated it disagrees with the regulator's findings but will not pursue an appeal. Executives cited the negligible financial impact of the revocation, noting that the vaccine was not being actively distributed in the region due to sluggish demand from travelers. Because no physical stock remains on the market, the company does not anticipate any recall-related expenses or significant revenue losses.

This regulatory reversal is confined strictly to the United Kingdom. Ixchiq retains its product licenses across the European Union, Canada, and Brazil, where distribution remains unaffected by the British ruling. The vaccine, designed to combat the chikungunya virus, reached the U.K. market earlier in 2025 before being sidelined by low sales volume.